MB
NTLA icon

MPM BioImpact’s Intellia Therapeutics NTLA Stock Holding History

MPM BioImpact’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-267,557
Closed -$5.5M – 51
2024
Q3 		$5.5M Sell
267,557
-175,946
-40% -$4.06M 0.82% 32
2024
Q2 		$9.93M Buy
443,503
+10,905
+3% +$260K 1.54% 24
2024
Q1 		$11.9M Buy
432,598
+50,000
+13% +$1.39M 1.91% 17
2023
Q4 		$11.7M Sell
382,598
-162,041
-30% -$4.66M 2.73% 13
2023
Q3 		$17.2M Hold
544,639
– – 4.6% 6
2023
Q2 		$22.2M Sell
544,639
-27,820
-5% -$1.13M 4.47% 7
2023
Q1 		$21.3M Buy
572,459
+117,221
+26% +$4.6M 5.54% 6
2022
Q4 		$15.9M Buy
455,238
+80,829
+22% +$3.84M 4.12% 8
2022
Q3 		$21M Buy
374,409
+75,000
+25% +$4.65M 4.96% 5
2022
Q2 		$15.5M Buy
299,409
+140,000
+88% +$7.11M 4.3% 5
2022
Q1 		$11.6M Sell
159,409
-1,118
-0.7% -$94.7K 3.11% 6
2021
Q4 		$19M Sell
160,527
-2,093
-1% -$262K 3.46% 8
2021
Q3 		$21.8M Buy
+162,620
New +$24.6M 3.38% 9

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MPM BioImpact's NTLA Position: Q4 2024 in Review

MPM BioImpact sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 267,557 shares — an estimated $5.5M sold.

MPM BioImpact first reported a position in NTLA in Q3 2021 and held it in 13 quarters. The position peaked at $22.2M in Q2 2023. 295 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • MPM BioImpact reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • MPM BioImpact sold 267,557 Intellia Therapeutics shares in Q4 2024, an estimated $5.5M.
  • MPM BioImpact first reported a position in Intellia Therapeutics in Q3 2021 and held it in 13 quarters.
  • MPM BioImpact's Intellia Therapeutics position peaked at $22.2M in Q2 2023.
  • 295 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on MPM BioImpact's 13F filing for Q4 2024, filed 14 Feb 2025.